CJRB 401
Alternative Names: CJRB-401Latest Information Update: 21 Sep 2023
At a glance
- Originator CJ Bioscience
- Class Antiallergics; Bacteria
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Asthma
Most Recent Events
- 28 Jul 2023 Preclinical trials in Asthma in South Korea (unspecified route) before July 2023 (CJ Biosciences pipeline, July 2023)